Isolated cortical vein thrombosis after nitrous oxide use in a young woman: a case report

Mao Liu, Jing Zhang and Bitao Bu

Abstract

Background: Nitrous oxide has become a popular inhalant as abused substance by young Chinese people in recent years. It has been mainly associated with medical conditions including megaloblastic anemia and myeloneuropathy.

Case presentation: We report a case of a 25-year-old high school graduate who had been abusing nitrous oxide for twenty months. She had a history of peripheral neuropathy and subacute combined degeneration in between. The young woman presented with headache, motor aphasia and right arm paralysis of eight hours after intermittently consuming nitrous oxide for one week. D-dimer was increased (1.1 mg/ml). Blood vitamin B12, folate, homocysteine and beta-HCG levels were normal. Head CT showed hemorrhagic infarction and subarachnoid hemorrhage. MR angiography and venography were normal. Head MRI identified left frontal isolated cortical vein thrombosis. Her muscle strength and verbal fluency significantly improved after initiation of Low Molecular Weight Heparin and serial head MRI showed continuous reduction in the size of thrombus.

Conclusions: For the first time nitrous oxide use is found to be related to isolated cortical vein thrombosis. Public education regarding the potential consequences of abuse of nitrous oxide especially in high-risk individuals is urgently needed.

Keywords: Nitrous oxide, Subacute combined degeneration, Peripheral neuropathy, Isolated cortical vein thrombosis, Case report

Background

Nitrous oxide has been widely used as an anesthetic agent in the medical field. However, previous studies have found its use is associated with various medical conditions including macrocytic anemia, peripheral neuropathy, subacute combined degeneration, deep vein thrombosis, pulmonary embolism, aortic thrombosis and cerebral venous sinus thrombosis [1–20]. Here for the first time we report a young woman with isolated cortical vein thrombosis related to nitrous oxide use.

Case presentation

Medical history

A 25-year-old Chinese woman presented with headache and difficulty in speaking and moving the right arm for the last eight hours. She used oral contraceptives once ten days ago and inhaled nitrous oxide outside with friends in the last week.

The patient began to use oxide intermittently twenty months ago. She gradually developed numbness and weakness of distal limbs, and balance difficulty, which significantly improved after vitamin B12 intake of one month. One year ago her numbness in the distal limbs subacutely deteriorated and ascended to both proximal thighs and the upper trunk. Medical record showed she had impaired superficial sensation of both hands, feet and the thorax region from T4 to T8 dermatome,

* Correspondence: bubitao@tjh.tjmu.edu.cn
1 Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China

Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
impaired deep sensation of the lower limbs, and areflexia. MRI showed hyper-intensities involving the posterior and lateral column of the spine cord ranging from T5 to T11 vertebral body on T2 sequence (not shown). A diagnosis of peripheral neuropathy and subacute combined degeneration was made and her symptoms again improved significantly with vitamin B12 intake. The patient did not use other substances and had no family history.

**Neurological examination**
The patient had significant motor aphasia, mild right facial paralysis and right deviation of tongue. Muscle strength of the right upper limb is 0/5 with reduced tendon reflex compared with the left side. No apparent abnormalities in mental status, sensations and coordination were found.

**Diagnostic tests and treatment**
Erythrocyte sedimentation rate (34 mm/H), c-reaction protein (21.1 mg/L), D-Dimer (1.14 ug/ml) and lactate dehydrogenase (314 U/L) were elevated. Complete blood count, liver enzyme, creatinine, urea nitrogen, troponin I, protein C, protein S, antinuclear antibodies, autoantibodies to extractable nuclear antigens, antiphospholipid antibodies, anti-neutrophil cytoplasmic antibodies, and beta-HCG were all within normal limits. Folate and vitamin B12 levels were normal. Homocysteine level was within the upper limit (13.6 umol/L; normal range 6–14 umol/L). No mutation of Factor V Leiden was found. Methylenetetrahydrofolate reductase (MTHFR) genotype of C677T and A1298C, and plasminogen activator inhibitor 1 (PAI-1) genotype of 4G/5G were confirmed.

Head CT showed hemorrhagic infarction (Fig. 1a&b, arrow) and subarachnoid hemorrhage (Fig. 1b, arrow heads) mainly involving the left parietal lobe. MR angiography and venography were normal (not shown) and excluded major abnormalities of the large and medium arteries as well as the venous sinus system. Since the patient did not experience any major symptomatic improvement during the hospital stay and there was the concern about the existence of isolated cortical vein thrombosis, MRI head with 0.1 mm thickness demonstrated expanding hematoma and edema causing cingulate herniation, and confirmed isolated cortical vein thrombosis over the frontal cortical surface in the sagittal, coronal and axial section (Fig. 2a-c) ten days after admission.

Vitamin B6, B12, folate, mannitol and Low Molecular Weight Heparin were initiated. The sizes of thrombus, hematoma and edema reduced continuously after treatment of five (Fig. 2d-f) and twelve days (Fig. 2g-i), respectively, and the patient achieved significant improvement in muscle strength (grade 3/5) and verbal fluency in the meantime. Anticoagulation was switched from Low Molecular Weight Heparin to oral anticoagulant after another two weeks and the patient was discharged.

**Outcome**
During the last follow-up (6 weeks after symptom onset), the patient had further improvement in muscle strength (grade 4/5) and almost normalized verbal fluency. The patient was satisfied with her recovery and no adverse effects were reported.

**Discussion and conclusion**
In this report we described a young Chinese woman with isolated cortical vein thrombosis [21] related to nitrous oxide use. Her history of peripheral neuropathy and subacute combined degeneration was most probably also attributed to nitrous oxide. To our knowledge this is the first case report on the association between nitrous oxide use and isolated cortical vein thrombosis in the existing literatures.

Nitrous oxide has gained its popularity among young people worldwide for many years [22] and also among Chinese people in recent years. Nitrous oxide produces analgesic and anxiolytic effects upon inhalation [22] and has abuse potential [13]. Nitrous oxide could potently

---

**Fig. 1** Head CT upon admission showed hemorrhagic infarction mainly involving the left parietal lobe (a-c, arrow) and subarachnoid hemorrhage (c, arrow heads)
change cobalamin from reduced to oxidized state [23]; the lack of bioavailable cobalamin disrupts the normal function of methionine synthase which requires both reduced cobalamin and folate as cofactors [24]. Reduced methionine further leads to reduced S-adenosylmethionine production, which is associated with defective DNA maturation, megaloblastic changes of red blood cells [24] and abnormal myelination of nerve fibers [25]. This is supported by numerous previous individual reports and systematic reviews on the incidence of megaloblastic anemia, peripheral neuropathy and subacute combined degeneration related to nitrous oxide [1–16], and also in line with a history of peripheral neuropathy and subacute combined degeneration of our patient.

Much less frequently reported were incidences of thrombotic events related to chronic use of nitrous oxide. Den Uil et al. reported a 32-year-old male with aortic arch thrombus formation, increased homocysteine and decreased vitamin B level, and a heterozygous factor II mutation [19]. Bajaj et al. described a 32-year-old male with ischemic stroke, decreased vitamin B12 and folate level, and increased homocysteine level [20]. Sun et al. reported a 29-year-old male with deep vein thrombosis, pulmonary embolism and homocysteinemia [18].

Fig. 2  Head MRI ten days after admission showed isolated cortical vein thrombosis (arrow head) over the frontal cortical surface and expanding hematoma and edema (double arrow head) that caused cingulate hemiation in the sagittal, coronal and axial section (a–c) on T2 SPACE sequence. The sizes of thrombosis (arrow head), hematoma and edema (double arrow head) continuously decreased on T1 CUBE sequence after five (d–f) and twelve (g–i) days of anticoagulation, respectively.
et al. presented a 21-year-old female with a large cerebral venous sinus thrombosis with elevated homocysteine and methylmalonic acid level, normal cobalamin and folate levels. The patient was also pregnant and had significant MTHFR polymorphisms [17]. Previous studies showed that MTHFR genotype polymorphisms including C677T and A1298C were associated with elevated homocysteine levels [26, 27]; homocysteinemia was again associated with increased risk of venous thrombosis [28, 29]. Furthermore, oral contraceptive has been associated with increased thrombotic risk in women [30, 31]. While in all the above mentioned case reports there was consistent elevation of homocysteine level, our patient only had a high normal homocysteine level. Our patient had normal protein C, protein S and beta-HCG levels; Factor V Leiden mutation was not found. Thus, it cannot be excluded that the use of nitrous oxide by our patient in the preceding week of stroke still increased the homocysteine level (homocysteine level was 9 umol/L one year ago when the diagnosis of subacute combined degeneration was made) and contributed to a hypercoagulable state [32] together with oral contraceptive use. Our patient also had PAI-1 4G/5G polymorphism. However, it is to note that a recent study did not find a higher risk of venous thrombosis related to PAI-1 4G/5G polymorphism [33], and it is uncertain what role it played in the thrombotic event in our patient.

A major limitation is that we could not screen for all types of hereditary thrombophilia to exclude effects of other unknown conditions. However, considering the close temporal relationship between nitrous oxide use and the incidence of isolated cortical vein thrombosis in our patient who had a clear past history of medical conditions associated with nitrous oxide use, we believe nitrous oxide use had at least partly contributed to the formation of isolated cortical vein thrombosis in our patient despite of scare reports from existing literatures [17–20].

In conclusion, nitrous oxide use could be associated with thrombotic events including isolated cortical vein thrombosis, especially in individuals with other factors predisposing to a hypercoagulable state apart from diseases of the hematological and neurological systems. Early recognition and treatment of isolated cortical vein thrombosis is critical. Considering its easy accessibility among young people, it is of great importance to raise public consciousness of the potential negative effects of nitrous oxide use on young individuals.

Abbreviations
MTHFR: Methylenetetrahydrofolate reductase; PAI-1: Plasminogen activator inhibitor 1

Acknowledgements
Not applicable.

Authors’ contributions
LM contributed to data collection, data interpretation, figure production, study design, and writing. ZJ contributed to data collection, data interpretation, and figure production. BB contributed to data interpretation and study design. All Authors have read and approved this manuscript.

Funding
Not applicable.

Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analyzed for this study.

Ethics approval and consent to participate
Written informed consent to participate was obtained from this patient.

Consent for publication
Written informed consent for publication of medical information and figures was obtained from this patient.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China.
2. Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China.

Received: 4 June 2020 Accepted: 15 October 2020
Published online: 20 October 2020

References
1. Amess JA, Burman JF, Rees GM, Nancekivell DG, Mollin DL. Megaloblastic haemopoiesis in patients receiving nitrous oxide. Lancet. 1978;2(8085):339–42. https://doi.org/10.1016/s0140-6736(78)92941-0.
2. Nunn JF, Sharer NM, Gorchein A, Jones JA, Wickramasinghe SN. Megaloblastic haemopoiesis after multiple short-term exposure to nitrous oxide. Lancet. 1982;1(8286):1379–81. https://doi.org/10.1016/s0140-6736(82)92949-0.
3. Blanco G, Peters HA. Myeloneuropathy and macrocytosis associated with nitrous oxide abuse. Arch Neurol. 1983;40(7):416–8. https://doi.org/10.1001/archneur.1983.04050070046009.
4. Sesso RM, Iunes Y, Melo AC. Myeloneuropathy following nitrous oxide anaesthesia in a patient with macrocytic anaemia. Neuroradiology. 1999; 41(5):588–90. https://doi.org/10.1007/s0023400502613.
5. Barboa L, Leal J, Timoteo AT, Matias T. Acute megaloblastic anaemia caused by inhalation of nitrous oxide in a patient with multiple autoimmune pathology. Acta Med Port. 2000;13(5–6):309–12. .
6. Felmet K, Robins B, Tilford D, Hayflick SJ. Acute neurologic decapsulation in an infant with cobalamin deficiency exposed to nitrous oxide. The Journal of Pediatrics. 2000;137(3):427–8. https://doi.org/10.1067/mpd.2000.107387.
7. Ahn SC, Brown AW. Cobalamin deficiency and subacute combined degeneration after nitrous oxide anesthesia: a case report. Arch Phys Med Rehabil. 2005;86(1):150–3. https://doi.org/10.1016/j.apmr.2004.01.019.
8. Cohen Aurbart F, Sedef F, Vicart S, Lyon-Caen O, Fontaine B. Nitric-oxide triggered neurological disorders in subjects with vitamin B12 deficiency. Revue neurologique. 2007;163(3):362–4. https://doi.org/10.1016/j.neuro.2005-3787807900409-9.
9. Shulman RM, Geraghty TJ, Tadros M. A case of unusual substance abuse causing myeloneuropathy. Spinal cord. 2007;45(4):314–7. https://doi.org/10.1038/sj.sc.3101962.
10. Singer MA, Lazaridis C, Nations SP, Wolfe GI. Reversible nitrous oxide-induced myeloneuropathy with pemiocin anemia: case report and literature review. Muscle Nerve. 2008;37(1):125–9. https://doi.org/10.1002/mus.20840.
11. Cheng HM, Park JH, Herrnstadt D. Subacute combined degeneration of the spinal cord following recreational nitrous oxide use. BMJ Case Rep. 2013; 2013; doi: https://doi.org/10.1136/bcr-2012-008509.
12. Thompson AG, Leite M, Lunn MP, Bennett DL. Whippits, nitrous oxide and the dangers of legal highs. Practical neurology. 2015;15(3):207–9. https://doi.org/10.1136/practneurol-2014-001071.

13. Garakani A, Jaffe RJ, Savla D, Welch AK, Protn I, Bryson E0, et al. Neurologic, psychiatric, and other medical manifestations of nitrous oxide abuse: a systematic review of the case literature. Am J Addictions. 2016;25(5):358–69. https://doi.org/10.1111/ajad.12372.

14. Middleton J, Roffers JA. Peripheral neuropathy due to recreational use of nitrous oxide presenting after an ankle sprain with foot drop. Orthopedics. 2018;41(3):e342–3. https://doi.org/10.3928/01477447-20171102-05.

15. Patel RK, Meija Munne JC, Gunness VRN, Hersey D, Alishaf N, Scibb D, et al. Subacute combined degeneration of the spinal cord following nitrous oxide anesthesia: a systematic review of cases. Clin Neurol Neurosurg. 2018;173:163–8. https://doi.org/10.1016/j.clineuro.2018.08.016.

16. Lan SY, Kuo CY, Chou CC, Kong SS, Hung PC, Tsai HY, et al. Recreational nitrous oxide abuse related subacute combined degeneration of the spinal cord in adolescents - a case series and literature review. Brain Develop. 2019;41(5):428–35. https://doi.org/10.1016/j.braindev.2018.12.003.

17. Piatt DN, Patterson KC, Qun K. Venous thrombosis after nitrous oxide abuse, a case report. J Thromb Thrombolysis. 2020;49(3):501–3. https://doi.org/10.1007/s11239-019-02010-9.

18. Sun W, Lao JP, Hu Y, Zhang W, Ma J, Wang GF. Pulmonary embolism and deep vein thrombosis caused by nitrous oxide abuse: a case report. World J Clin Cases. 2019;7(23):4057–62. https://doi.org/10.12998/wjcc.v7i23.4057.

19. den Uil SH, Vermeulen EGJ, Metz R, Rijbroek A, de Vries M. Aortic arch thrombus caused by nitrous oxide abuse. J VascSurg Cases Innovative Tech. 2018;4(2):80–2. https://doi.org/10.1016/j.jvscit.2018.01.001.

20. Bajaj D, Agrawal A, Gupta S, Bajaj S. Recreational nitrous oxide abuse causing ischemic stroke in a young patient: a rare case report. Cureus. 2018;10(12):e3761. https://doi.org/10.7759/cureus.3761.

21. Coutinho JM, Gerritsma JJ, Zuurbier SM, Stam J. Isolated cortical vein thrombosis: systematic review of case reports and case series. Stroke. 2014;45(6):1836–8. https://doi.org/10.1161/STROKEAHA.113.004414.

22. Emmanouil DE, Quock RM. Advances in understanding the actions of nitrous oxide. Anesth Prog. 2007;54(1):9. https://doi.org/10.1016/j.braindev.2018.12.003.

23. Chanarin I. Cobalamins and nitrous oxide: a review. J Clin Pathol. 1980;33(10):909–16. https://doi.org/10.1136/jcp.33.10.909.

24. Chanarin I. The effects of nitrous oxide on cobalamin, folates, and on related events. Crit Rev Toxicol. 1982;10(3):179–213. https://doi.org/10.3109/10408448209037455.

25. Funjo M, Kinosita M, Nagao M, Kubo T. Methionine adenosyltransferase I/III deficiency: neurological manifestations and relevance of S-adenosylmethionine. Mol Genet Metab. 2012;107(3):253–6. https://doi.org/10.1016/j.ymgme.2012.08.002.

26. Wang F, Sui X, Xu N, Yang J, Zhao H, Fei X, et al. The relationship between plasma homocysteine levels and MTHFR gene variation, age, and sex in northeast China. Nigerian Journal of Clinical Practice. 2019;22(3):380–5. https://doi.org/10.1016/j.magen.2014.10.004.

27. Liew SC, Gupta ED. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases. European Journal of Medical Genetics. 2015;58(1):1–10. https://doi.org/10.1016/j.ejmg.2014.10.004.

28. Quere I, Gris JC, Dauzat M. Homocysteine and venous thrombosis. Seminars in Vascular Medicine. 2005;5(2):183–9. https://doi.org/10.1055/s-2005-82403.

29. Gatt A, Makris M. Hyperhomocysteinemia and venous thrombosis. Semin Hematol. 2007;44(2):70–7. https://doi.org/10.1055/s-1003-001002.

30. Gialeraki A, Valsami S, Pittaras T, Panayiotakopoulos G, Politou M. Oral contraceptives and HRT Risk of Thrombosis. Clin Appl Thromb Hemost. 2018;24(2):217–25. https://doi.org/10.1097/MBC.0000000000000656.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Liu et al. BMC Neurology (2020) 20:378

Page 5 of 5